Skip to main content
Caplight Logo









Dispatch Biotherapeutics

Dispatch Biotherapeutics

Private
Philadelphia, PennsylvaniaHealthcare & Life Scienceshttps://dispatchbio.com/

Last Round

Series A

Jul 23, 2025

Total Funding Raised

$216M

Company Overview

Dispatch Biotherapeutics is a biotechnology company that develops immunotherapy-based cancer treatment technologies designed to expand curative potential across solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immunotherapysolid tumor treatmentbiotechnologyoncologyclinical-stage biotechdrug discoveryclinical trialsCAR-T therapytherapeutic pipelinebiopharmacancer researchinvestigational new drugINDbiologicstumor-selective virus

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Dispatch Biotherapeutics Comparables

Compare Dispatch Biotherapeutics with similar companies based on industry and business-model similarity.

Dispatch Biotherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CREATE Medicines
81%
Eureka Therapeutics
77%
ArsenalBio
76%

Dispatch Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJul 23, 2025

Key People

Founding team and executive leadership

Lexus Johnson

Co-Founder, Chief Platform Officer

Founding Team

Sabah Öney

Chief Executive Officer

Executive Team

Dispatch Biotherapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2026

    Collaboration with University of Pennsylvania and other leading institutions.

  • Jan 16, 2026

    Partnering with CARsgen Therapeutics to develop CAR-T cell therapies.

Dispatch Biotherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Dispatch Biotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Dispatch Biotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersPhiladelphia, Pennsylvania
Employee Range64
Year Founded2022
Last FundingJul 23, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?